Wedbush Morgan downgrades Inspire Pharmaceuticals (Nasdaq: ISPH) from Outperform to Neutral

Wedbush analyst says, "Topline Phase 1 glaucoma data suggests ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE